Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a ...

Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) ...

NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in ...

Soligenix (SNGX) stock surged on Thursday after the late-stage biopharmaceutical company announced results from its Phase 2a ...

After underperforming the overall market for the past few years, large-cap pharmaceutical stocks may now be positioned to ...

Patients with BS are associated with disrupted sleep quality that appears to be driven by active disease status and comorbid fibromyalgia.

Soligenix Inc.’s phase IIa study of SGX-945 (dusquetide) for treating oral ulcers in those with Behçet's disease showed biological efficacy in the proof-of-concept study. The positive results ...

Chronic fatigue syndrome is characterized by severe symptoms that significantly impair physical and mental activities, including persistent fatigue, sleep abnormalities, dizziness, and chronic pain.

In recent years, doctors and scientists are increasingly studying long-lasting illnesses that begin after someone recovers from an infection. Two of the most well-known examples are long COVID and ...

Discover how gut microbiome research could lead to a diagnostic test for chronic fatigue syndrome and new treatment options.

When Gretchen Dunoyer heard that the Massachusetts Institute of Technology was recruiting people with lingering Lyme disease symptoms for a study, she burst into tears. Dunoyer, 63, had near ...